Gene editing and CRISPR-based therapies by Editas Medicine
Editas Medicine CEO to join MIT panel on pipeline prioritization at Longwood Healthcare Leaders event
Editas Medicine announced that its President and CEO, Gilmore O’Neill, will participate in the upcoming Longwood Healthcare Leaders MIT CEO 2026 Meeting. He is scheduled to join industry peers ...
Editas Medicine adjusts agenda at key investor event
Editas Medicine has updated the scheduled presentation time for its upcoming appearance at an investor conference. The company directed stakeholders to its full press release for detailed ...
Editas Medicine presents new preclinical data on EDIT-401 at EASCongress2026
Editas Medicine presented new preclinical data this week at EASCongress2026, focusing on the progress of its lead in vivo development candidate, EDIT-401. The company provided details supporting ...
Editas Medicine prepares to present in vivo candidate data at EAS Congress in Athens
Editas Medicine will attend the 94th European Atherosclerosis Society Congress in Athens next week, where it plans to present new preclinical findings on its lead in vivo development candidate, ...
Editas Medicine presents new in vivo gene editing data on EDIT-401 at TIDES USA 2026 Meeting
Editas Medicine announced the presentation of new insights on its lead in vivo development candidate, EDIT-401, during the TIDES USA 2026 Meeting. The oral presentation highlights the ...
Editas Medicine unveils cardiovascular research at ASGCT and TIDES USA events
Editas Medicine is set to present new preclinical data this week at both the American Society of Gene and Cell Therapy (ASGCT) and TIDES USA annual meetings. The focus will be on cardiovascular ...
Editas Medicine posts first quarter 2026 results and provides business update
Editas Medicine announced its financial results for the first quarter of 2026, along with key business updates. The company, specializing in gene editing technologies targeting cardiovascular ...
Upcoming Editas Medicine presentations focus on gene editing research advances
Editas Medicine announced it will present new preclinical data at upcoming scientific conferences. The company indicated that the research will cover recent developments in gene editing ...
Editas Medicine posts fourth quarter and full year 2025 financial results
Editas Medicine announced its financial results for the fourth quarter and full year 2025. The company also shared updates on its business operations and strategic plans. Full details are ...
Editas Medicine achieves significant LDL reduction with EDIT-401 therapy
Editas Medicine, a leader in gene editing, announces a breakthrough in LDL cholesterol reduction with its experimental therapy, EDIT-401. The company reports the therapy achieved a mean reduction ...
Editas Medicine unveils EDIT-401 data at AHA 2025
Editas Medicine has announced the upcoming presentation of their EDIT-401 data at the American Heart Association (AHA) Scientific Sessions scheduled for 2025. This event will mark a significant ...
